Data-driven microbiota biomarker discovery for personalized drug therapy of cardiovascular disease.

[1]  Robert D. Finn,et al.  A unified catalog of 204,938 reference genomes from the human gut microbiome , 2020, Nature Biotechnology.

[2]  Chee Keong Kwoh,et al.  Predicting Human Microbe-Drug Associations via Graph Convolutional Network with Conditional Random Field , 2020, Bioinform..

[3]  Bairong Shen,et al.  Heart rate variability based prediction of personalized drug therapeutic response: the present status and the perspectives. , 2020, Current topics in medicinal chemistry.

[4]  Xiujuan Lei,et al.  Predicting Microbe-Disease Association by Learning Graph Representations and Rule-Based Inference on the Heterogeneous Network , 2020, Frontiers in Microbiology.

[5]  M. Mahmoudi,et al.  Gut microbiota and cardiovascular disease: opportunities and challenges , 2020, Microbiome.

[6]  M. Mayr,et al.  Noncoding RNAs versus Protein Biomarkers in Cardiovascular Disease. , 2020, Trends in molecular medicine.

[7]  Oliver Fiehn,et al.  A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic Receptors , 2020, Cell.

[8]  Jing Ma,et al.  Gut microbial taxa as potential predictive biomarkers for acute coronary syndrome and post-STEMI cardiovascular events , 2020, Scientific Reports.

[9]  Lequan Yu,et al.  MS-Net: Multi-Site Network for Improving Prostate Segmentation With Heterogeneous MRI Data , 2020, IEEE Transactions on Medical Imaging.

[10]  C. Vlachopoulos,et al.  Periodontitis and cardiovascular diseases: Consensus report , 2020, Journal of clinical periodontology.

[11]  Bairong Shen,et al.  Phenotype–genotype network construction and characterization: a case study of cardiovascular diseases and associated non-coding RNAs , 2020, Database J. Biol. Databases Curation.

[12]  M. Rogero,et al.  The Two-Way Polyphenols-Microbiota Interactions and Their Effects on Obesity and Related Metabolic Diseases , 2019, Front. Nutr..

[13]  Dominik G Grimm,et al.  Current challenges and best-practice protocols for microbiome analysis , 2019, Briefings Bioinform..

[14]  U. Eriksson,et al.  Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy , 2019, Science.

[15]  M. Garelnabi,et al.  Polyphenolic compounds and gut microbiome in cardiovascular diseases. , 2019, Current pharmaceutical biotechnology.

[16]  Robert D. Finn,et al.  MGnify: the microbiome analysis resource in 2020 , 2019, Nucleic Acids Res..

[17]  Bairong Shen,et al.  MIRKB: a myocardial infarction risk knowledge base , 2019, Database J. Biol. Databases Curation.

[18]  E. Sanders,et al.  Impact of delivery mode-associated gut microbiota dynamics on health in the first year of life , 2019, Nature Communications.

[19]  Liang Cheng,et al.  gutMDisorder: a comprehensive database for dysbiosis of the gut microbiota in disorders and interventions , 2019, Nucleic acids research.

[20]  D. Panagiotakos,et al.  Mining possible associations of faecal A. muciniphila colonisation patterns with host adiposity and cardiometabolic markers in an adult population. , 2019, Beneficial microbes.

[21]  Ashutosh Gupta,et al.  Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency , 2019, Nutrients.

[22]  J. Ferguson,et al.  The Gut Microbiome and Response to Cardiovascular Drugs. , 2019, Circulation. Genomic and precision medicine.

[23]  Bairong Shen,et al.  Translational Informatics for Parkinson’s Disease: from Big Biomedical Data to Small Actionable Alterations , 2019, Genom. Proteom. Bioinform..

[24]  G. Condorelli,et al.  MicroRNAs as Companion Biomarkers for the Diagnosis and Prognosis of Acute Coronary Syndromes. , 2019, Circulation research.

[25]  Juan Xu,et al.  Landscape of the long non-coding RNA transcriptome in human heart , 2019, Briefings Bioinform..

[26]  R. Xavier,et al.  Gut Microbial Associations to Plasma Metabolites Linked to Cardiovascular Phenotypes and Risk. , 2019, Circulation research.

[27]  J. Auwerx,et al.  The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans , 2019, Nature metabolism.

[28]  Bairong Shen,et al.  Computer-aided biomarker discovery for precision medicine: data resources, models and applications , 2019, Briefings Bioinform..

[29]  Andrew D. Johnson,et al.  70-year legacy of the Framingham Heart Study , 2019, Nature Reviews Cardiology.

[30]  Q. Yu,et al.  Using herbal medicine to target the "microbiota-metabolism-immunity" axis as possible therapy for cardiovascular disease. , 2019, Pharmacological research.

[31]  Lihui Zhao,et al.  Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality , 2019, JAMA.

[32]  Sonika Bhatnagar,et al.  MorCVD: A Unified Database for Host-Pathogen Protein-Protein Interactions of Cardiovascular Diseases Related to Microbes , 2019, Scientific Reports.

[33]  D. Figeys,et al.  RapidAIM: a culture- and metaproteomics-based Rapid Assay of Individual Microbiome responses to drugs , 2019, Microbiome.

[34]  Yasukiyo Yoshioka,et al.  Role of Intestinal Microbiota in the Bioavailability and Physiological Functions of Dietary Polyphenols , 2019, Molecules.

[35]  Xing Chen,et al.  MDAD: A Special Resource for Microbe-Drug Associations , 2018, Front. Cell. Infect. Microbiol..

[36]  T. Yanagita,et al.  Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism , 2018, Lipids in Health and Disease.

[37]  D. Bruner,et al.  Composition of gut microbiota and its association with body mass index and lifestyle factors in a cohort of 7–18 years old children from the American Gut Project , 2018, Pediatric obesity.

[38]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[39]  Holger Husi,et al.  C/VDdb: A multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD) , 2018, bioRxiv.

[40]  E. Diamandis,et al.  Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers? , 2018, Critical reviews in clinical laboratory sciences.

[41]  R. Horst,et al.  Role of gut microbiota in chronic low‐grade inflammation as potential driver for atherosclerotic cardiovascular disease: a systematic review of human studies , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[42]  Siu-Ming Yiu,et al.  BMCMDA: a novel model for predicting human microbe-disease associations via binary matrix completion , 2018, BMC Bioinformatics.

[43]  J. Tu,et al.  Development and validation of a cardiovascular disease risk-prediction model using population health surveys: the Cardiovascular Disease Population Risk Tool (CVDPoRT) , 2018, Canadian Medical Association Journal.

[44]  M. Nieuwenhuijsen.  Influence of urban and transport planning and the city environment on cardiovascular disease , 2018, Nature Reviews Cardiology.

[45]  R. Kizek,et al.  Contribution of Red Wine Consumption to Human Health Protection , 2018, Molecules.

[46]  J. Nielandt,et al.  Disbiome database: linking the microbiome to disease , 2018, BMC Microbiology.

[47]  Jim Warren,et al.  Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study , 2018, The Lancet.

[48]  Yongzhong Zhao,et al.  Gut microbiota derived metabolites in cardiovascular health and disease , 2018, Protein & Cell.

[49]  Jingyuan Fu,et al.  Pharmacomicrobiomics: a novel route towards personalized medicine? , 2018, Protein & Cell.

[50]  L. Gesualdo,et al.  Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease , 2018, Pharmacological research.

[51]  L. Carrera-Quintanar,et al.  Phytochemicals That Influence Gut Microbiota as Prophylactics and for the Treatment of Obesity and Inflammatory Diseases , 2018, Mediators of inflammation.

[52]  A. Crozier,et al.  Trimethylamine-N-Oxide (TMAO)-Induced Impairment of Cardiomyocyte Function and the Protective Role of Urolithin B-Glucuronide , 2018, Molecules.

[53]  S. Hazen,et al.  Microbial modulation of cardiovascular disease , 2018, Nature Reviews Microbiology.

[54]  Xun Xu,et al.  The gut microbiome in atherosclerotic cardiovascular disease , 2017, Nature Communications.

[55]  Ankit Sharma,et al.  In-Cardiome: integrated knowledgebase for coronary artery disease enabling translational research , 2017, Database J. Biol. Databases Curation.

[56]  M. D. de Goffau,et al.  A longitudinal study of the infant nasopharyngeal microbiota: The effects of age, illness and antibiotic use in a cohort of South East Asian children , 2017, PLoS neglected tropical diseases.

[57]  M. Kozioł-Montewka,et al.  Gut microbiome as a biomarker of cardiometabolic disorders. , 2017, Annals of agricultural and environmental medicine : AAEM.

[58]  D. Goff,et al.  Application of a Lifestyle-Based Tool to Estimate Premature Cardiovascular Disease Events in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study , 2017, JAMA internal medicine.

[59]  A. Crozier,et al.  In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats , 2017, Cardiovascular Diabetology.

[60]  J. Manson,et al.  Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta‐Analysis of Prospective Studies , 2017, Journal of the American Heart Association.

[61]  W. Tang,et al.  Therapeutic Strategies Targeting Inherited Cardiomyopathies , 2017, Current Heart Failure Reports.

[62]  J. Hippisley-Cox,et al.  Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study , 2017, British Medical Journal.

[63]  S. Hazen,et al.  Gut Microbiota in Cardiovascular Health and Disease , 2017, Circulation research.

[64]  Zhu-Hong You,et al.  A novel approach based on KATZ measure to predict associations of human microbiota with non‐infectious diseases , 2016, Bioinform..

[65]  E. Boerwinkle,et al.  Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. , 2016, The New England journal of medicine.

[66]  K. Griffiths,et al.  Food Antioxidants and Their Anti-Inflammatory Properties: A Potential Role in Cardiovascular Diseases and Cancer Prevention , 2016, Diseases.

[67]  F. Bernini,et al.  Antiatherogenic effects of ellagic acid and urolithins in vitro. , 2016, Archives of biochemistry and biophysics.

[68]  R. Osawa,et al.  Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study , 2016, BMC Microbiology.

[69]  Soonkyu Chung,et al.  Urolithin A, C, and D, but not iso-urolithin A and urolithin B, attenuate triglyceride accumulation in human cultures of adipocytes and hepatocytes. , 2016, Molecular nutrition & food research.

[70]  R. Milo,et al.  Revised Estimates for the Number of Human and Bacteria Cells in the Body , 2016, bioRxiv.

[71]  S. Hazen,et al.  Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis , 2015, Cell.

[72]  Andreas Wilke,et al.  The MG-RAST metagenomics database and portal in 2015 , 2015, Nucleic Acids Res..

[73]  J. Tu,et al.  Predicting Stroke Risk Based on Health Behaviours: Development of the Stroke Population Risk Tool (SPoRT) , 2015, PloS one.

[74]  R. Murugesan,et al.  CardioGenBase: A Literature Based Multi-Omics Database for Major Cardiovascular Diseases , 2015, PloS one.

[75]  A. von Eckardstein,et al.  Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. , 2015, Atherosclerosis.

[76]  S. Granica,et al.  Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages. , 2015, Molecular nutrition & food research.

[77]  Yan He,et al.  Dysbiosis of Gut Microbiota With Reduced Trimethylamine‐N‐Oxide Level in Patients With Large‐Artery Atherosclerotic Stroke or Transient Ischemic Attack , 2015, Journal of the American Heart Association.

[78]  S. Hazen,et al.  Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease , 2015, Circulation research.

[79]  Sonia S Anand,et al.  Cardiovascular disease in Asian Americans: unmasking heterogeneity. , 2014, Journal of the American College of Cardiology.

[80]  S. Hazen,et al.  Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. , 2014, Journal of the American College of Cardiology.

[81]  Jens Roat Kultima,et al.  An integrated catalog of reference genes in the human gut microbiome , 2014, Nature Biotechnology.

[82]  S. Granica,et al.  Influence of Gut Microbiota-Derived Ellagitanninsʼ Metabolites Urolithins on Pro-Inflammatory Activities of Human Neutrophils , 2014, Planta Medica.

[83]  R. Arce,et al.  Biomarkers of cardiovascular disease are increased in untreated chronic periodontitis: a case control study. , 2014, Australian dental journal.

[84]  Xiaojie Xu,et al.  CVDHD: a cardiovascular disease herbal database for drug discovery and network pharmacology , 2013, Journal of Cheminformatics.

[85]  Tatiana A. Tatusova,et al.  RefSeq microbial genomes database: new representation and annotation strategy , 2013, Nucleic Acids Res..

[86]  James R. Cole,et al.  Ribosomal Database Project: data and tools for high throughput rRNA analysis , 2013, Nucleic Acids Res..

[87]  P. Bork,et al.  Richness of human gut microbiome correlates with metabolic markers , 2013, Nature.

[88]  R. Tracy,et al.  T Helper Cell Polarization in Healthy People: Implications for Cardiovascular Disease , 2013, Journal of Cardiovascular Translational Research.

[89]  F. Tinahones,et al.  Benefits of polyphenols on gut microbiota and implications in human health. , 2013, The Journal of nutritional biochemistry.

[90]  M. Hattori,et al.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.

[91]  Xiang Li,et al.  CHD@ZJU: a knowledgebase providing network-based research platform on coronary heart disease , 2013, Database J. Biol. Databases Curation.

[92]  R. Krauss,et al.  Supplemental materials for: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013 .

[93]  F. Tinahones,et al.  Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. , 2012, The American journal of clinical nutrition.

[94]  Albert Gatt,et al.  BT-Nurse: computer generation of natural language shift summaries from complex heterogeneous medical data , 2011, J. Am. Medical Informatics Assoc..

[95]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[96]  Hui Liu,et al.  CADgene: a comprehensive database for coronary artery disease genes , 2010, Nucleic Acids Res..

[97]  Rob Knight,et al.  Human oral, gut, and plaque microbiota in patients with atherosclerosis , 2010, Proceedings of the National Academy of Sciences.

[98]  R. Knight,et al.  The Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice , 2009, Science Translational Medicine.

[99]  Richard McClatchey,et al.  A Data Model for Integrating Heterogeneous Medical Data in the Health-e-Child Project , 2008, HealthGrid.

[100]  S. Parkar,et al.  The potential influence of fruit polyphenols on colonic microflora and human gut health. , 2008, International journal of food microbiology.

[101]  G. Canny,et al.  Bacteria in the Intestine, Helpful Residents or Enemies from Within? , 2008, Infection and Immunity.

[102]  C. Kwik-Uribe,et al.  Flavanol monomer-induced changes to the human faecal microflora , 2007, British Journal of Nutrition.

[103]  W. Ludwig,et al.  SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB , 2007, Nucleic acids research.

[104]  E. Olson,et al.  A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.

[105]  M. Carrier,et al.  Oenology: Red wine procyanidins and vascular health , 2006, Nature.

[106]  F. Shanahan,et al.  The gut flora as a forgotten organ , 2006, EMBO reports.

[107]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[108]  Yang Wang,et al.  An analysis of human microbe‐disease associations , 2017, Briefings Bioinform..

[109]  Jiajia Chen,et al.  Interactions Between Genetics, Lifestyle, and Environmental Factors for Healthcare. , 2017, Advances in experimental medicine and biology.